Kornimate/medical-research-clean huggingface dataset:
early onset alzheimer's disease genomic study

Conditions: Alzheimer Disease

Summary: the purpose of this study is to collect samples from patients with early-onset alzheimer's disease (ad) and their immediate family members for molecular analysis. samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. researchers will study your dna and rna in order to help doctors diagnose, treat, and monitor people at risk of developing early-onset ad in the future.

about 50 people will be asked to take part in this study at this location. this will include participants with early-onset ad and their parents and siblings. participants will be asked to: sign this consent form or have a legally authorized representative sign and provide the participant' health history. the study staff will review the participant's medical history and test results to see if the participant can be part of this study, the study staff will need to know any over-the-counter or prescription drugs, vitamins, or herbs taken by the participant. the study staff will discuss what is required to be part of this study. participants cannot take part in this study if they have: family history of early or late-onset alzheimer's disease, uncontrolled concurrent illness including psychiatric illness or situations that would limit compliance with the study requirements or the ability to willingly give written or verbal consent. if the participant agrees to take part in this study, one 8ml blood sample (about 2 teaspoons) will be collected from them. if the participant is receiving a clinically indicated blood draw, the blood collections for this study will occur at the same time. participants may be required to have a research-specific blood draw if they are not scheduled for a blood draw during a regularly scheduled visit.

Eligibility criteria:
inclusion criteria: * diagnosis of early-onset alzheimer's disease based on the nia-aa diagnostic criteria as determined by the clinician. (those patients with severe dementia due to alzheimer's disease or who have impaired decisional capacity, may participate only if their legally authorized representative gives their consent.) * male and female patients ≥40 and ≤65 years of age. * parents and siblings of the participant with alzheimer's disease. exclusion criteria: * family history of early or late-onset alzheimer's disease. * uncontrolled concurrent illness including psychiatric illness or situations that would limit compliance with the study requirements or the ability to willingly give written or verbal informed consent

Keywords: early-onset alzheimer's disease
efficacy of mindfulness-based mobile application use in patients with depressive disorder

Conditions: Depression

Summary: the presented randomized-controled study aim to assess the use of internet-based mindfulness intervention via mobile application for 30 days in patients with major depressive disorder (mdd)

mindfulness-based interventions (mbi) proved to be effective in relapse prevention in mdd. next, mbi in form of free mobile applications can be an effective augmentation of the treatment as usual (tau) and can fill a gap in the ambulatory care. given this background, the aim of this randomized controlled study is to assess the effectiveness of additional mbi via mobile app on the symptom severity and stress levels, compared to tau.

Eligibility criteria:
inclusion criteria: * depression, current ill exclusion criteria: * acute alcohol- and drug dependency, schizophrenia or psychotic disorder, severe somatic illnes, not having smartphone or not willing to use mobile application
test to determine the effectiveness of moisturizing balm used on babies with dry, itchy skin

Conditions: Eczema

Summary: the purpose of this 3 week study is to test the effectiveness of an over-the-counter (otc) skin balm in infants and toddlers with mild to moderate dry, itchy skin.

50 infants and toddlers will be enrolled in this study to yield 40 completed subjects, 30 babies in the active treatment group and 10 babies in the positive control group. infants and toddlers aged 6 to 47 months inclusive will receive either a prescription or non-marketed investigational product for the treatment of eczema. caregivers will be asked to stop use of prescription eczema treatments one week before the start of the study and during the study. caregivers will apply study product to babies as indicated for 14 days to affected areas. subject caregivers will record treatment use in a daily diary and complete questionnaires. a dermatologist will examine and score the babies eczema and symptoms. skin moisture levels will also be tested.

Eligibility criteria:
inclusion criteria: 1. able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) 2. male or female of any race or ethnicity, 6 months to 47 months of age; 3. diagnosed as having eczema 4. willing to stop use of all non-assigned moisturizers and/or creams for the entire duration of the study 5. child must have bedtime/sleep issues due to their dry, itchy skin exclusion criteria: 1. use of a therapeutic (over-the-counter or prescription) body wash that contains an active ingredient for eczema 2. participation in any clinical study within 30 days of visit 1 3. active infection of any type at the start of the study 4. diagnosed as having severe eczema 5. atopic dermatitis requiring systemic, super-potent (class i) or potent (class ii or iii) topical corticosteroids 6. child wakes up 3 or more times during the night 7. child is awake more than 60 minutes during the night 8. child sleeps for less than a total of 9 hours (during the day or night) 9. child requires greater than 2.0 mg per day of inhaled or intranasal corticosteroids

Keywords: atopic dermatitis
the effects of visior on ocular hemodynamics

Conditions: Primary Open Angle Glaucoma

Summary: to determine the relationship between the affects of viewing commercially available content through the visior video goggles and ocular blood flow in glaucoma patients and healthy subjects.

to determine if glaucoma patients and healthy subject experience any alteration in localized retinal blood flow after retinal stimulation by viewing commercially available content through the visior video goggles. both groups will undergo measurements of arterial blood pressure, cardiac pulse (heart rate), intraocular pressure, and retinal blood flow using heidelberg retinal flowmetry (heidelberg engineering, heidelberg, germany) at baseline and then ten minutes, thirty minutes, and sixty minutes after viewing commercially available content through the visior video goggles for thirty minutes.

Eligibility criteria:
inclusion criteria: * patients with open-angle glaucoma 30 years or older, free from other ophthalmic disease, free from diabetes, beta agonists and uncontrolled blood pressure. exclusion criteria: * women who are pregnant or lactating or who plan to become pregnant (self reporting); smoker during last ten years (self reporting); systemic diseases that may interfere with blood flow measurements or wearing the goggles. * in addition, 10 healthy subjects, age 18 or older, free from eye disease will be enrolled. identical exclusion criteria apply to this healthy group. identical procedures apply to this group, which only differs by ocular health status.

Keywords: primary open-angle glaucoma retinal capillary blood flow visual stimulation
study of the effects of probiotics upon infectious episodes in subject aged more than 60, during winter.

Conditions: Infectious Episodes (ENT, Gastro-intestinal and Pulmonary)

Summary: we put forward that probiotics have an effect on infectious episodes evolution in subjects aged 60 years or over. the main objective of this research is to observe the effect of consumption of the probiotic on the average number of days with infectious episodes.


Eligibility criteria:
inclusion criteria: * subjects who accept not to alter their food habits exclusion criteria: * food allergy * regular consumption of probiotics * diabetes * respiratory deficiency * cardiac deficiency * cancer or chronicle disease not stabilized * splenectomy, sickle-cell anemia * immuno depression or immunodeficiency acquired or congenital * immuno depressor or corticoid treatments
radiofrequency ablation for multi-level obstructive sleep apnea: a single-arm, multicenter study

Conditions: Apnea, Sleep

Summary: the united states is currently experiencing an increase in the incidence and prevalence of obstructive sleep apnea (osa). with prevalence in middle-aged adults of 2 to 4% of the population, untreated osa has been implicated in increased risk for cardiovascular disease, including hypertension and heart failure, daytime sleepiness, and increased risk of motor vehicle accidents. this study was design in order to evaluate the celonprosleep plus for multi-level radiofrequency ablation (rfa) of the palate and base of tongue as a treatment for mild to moderate obstructive sleep apnea syndrome (osas).


Eligibility criteria:
inclusion criteria: * adults (≥ 22 years) * self-report of daytime somnolence * body mass index (bmi) ≤ 32 * mild to moderate obstructive sleep apnea (ahi 10 - 30; lowest o2 sat ≥ 80%) * evidence of palate and tongue base collapse on supine fiberoptic examination * non-compliant with or refusal of continuous positive airway pressure therapy (cpap) (\< 4 hours per night by patient report) * no prior surgical treatment for osas other than nasal surgery * willing and capable of providing informed consent exclusion criteria: * another significant sleep disorder (e.g., insomnia, periodic limb movement) * tonsillar hypertrophy * chronic obstructive pulmonary disease (copd) * interstitial lung disease (ild) * cystic fibrosis * acute repiratory distress syndrome (ards) * nasal or supraglottic obstruction on fiberoptic examination * american society of anesthesiologists (asa) class iii ,iv, v * latex allergy * lidocaine allergy * pregnancy or plans to become pregnant note: women of childbearing potential must demonstrate a negative pregnancy test upon enrollment; those patients qualified to progress to rfa must also demonstrate a negative pregnancy test within 7 days prior to the date of rfa procedure. * major depression or non-stabilized psychiatric disorder * drug or alcohol abuse * previous palatal or tongue surgery * stable or unstable angina * congestive heart failure (chf) * moderate or severe valvular disease * transient ischemic attack (tia)/cardiovascular accident (cva) * carotid stenosis or endarterectomy * anemia * room air oxygen saturation (spo2) \< 95% * pulmonary hypertension * dialysis * central or mixed apnea ≥ 10% of respiratory events * participation in another clinical study (enrolled in any concurrent study) whose investigational plan is judged to interfere or affect any of the measures of this study
on the phone respiratory rate study (opera)

Conditions: Respiratory Rate

Summary: introduction. the increasing use of telephone medical advice requires the development of telemedicine tools to assess the patient's severity. respiratory rate (rr) is a simple vital parameter and is often associated with morbidity and mortality of patients. there is no standardized measure of rr by telephone. objective: the investigators wanted to evaluate the rr measurement by phone using a smartphone application called rrate. methods. adults who have been admitted for less than 6 hours to the emergency department after calling center 15 and whose main reason for consultation is dyspnea will be included. patients with non-invasive or tracheotomized ventilation will be excluded. the main objective will be to compare by bland-altman method the accuracy of the rrate measurement by phone to a one-minute rr measurement at patient's bedside. secondary endpoints will evaluate the length of rr measurement according to the different methods used; measurement failure criteria; the accuracy of different measurement techniques (rrate at patient's bedside, impedancemetry, traditional measurement during 15s or 30s). expected results. the accuracy of the rr measurement by rrate over the telephone should be within the limits of agreement. the measurement time should be shorter with the rrate application than with traditional methods. however, the measurement by telephone should not always be feasible in patients with mild dyspnea or with poorly audible breathing.


Eligibility criteria:
inclusion criteria: * age \>18yo * dyspnea as main reason for consultation * regulated by "centre 15" * admitted for less than 6hours at emergency department exclusion criteria: * non invasive or tracheotomized ventilation * cognitive impairment * pregnancy

Keywords: respiratory rate telemedicine dyspnea emergencies
a study to determine the capacity of vak694 when combined with allergen immunotherapy to bring about specific immune tolerance

Conditions: Seasonal Allergic Rhinitis

Summary: the purpose of the study is to determine whether vak694 when combined with subcutaneous immunotherapy leads to long term immune tolerance to allergen in individuals with seasonal allergic rhinitis.


Eligibility criteria:
inclusion criteria: * history of atopy, defined as a history of seasonal allergic rhinitis for at least 2 years (in relation to the grass pollen allergy season), and evidence of atopy, defined as a positive skin prick test (wheal difference allergen - negative control at least 3 mm) to grass pollen allergen at screening. * male or female subjects aged between 18 and 60 years (inclusive) * female subjects must be of non-childbearing potential * subjects must weigh at least 50 kg with a body mass index (bmi) within the range of 18 to 32 kg/m2 (inclusive) * informed consent exclusion criteria: * treatment with intranasal corticosteroids within 28 days prior to the first dose. * history of asthma with treatment with inhaled or systemic corticosteroids within 6 months of the first dose. * history of copd. * any exposure to human monoclonal or polyclonal antibodies. * any allergy immunotherapy within 3 years prior to screening. * any prior grass pollen allergy immunotherapy. * fev1 \< 70% of predicted at screening or baseline. other protocol-defined inclusion/exclusion criteria may apply

Keywords: seasonal allergic rhinitis, late phase response, alutard avanz, immunotherapy, visual analogue scale, mini rhinitis quality of life, immune modulation
successful extubation and noninvasive ventilation in preterm ≤ 1500g terms

Conditions: Respiratory Distress Syndrome In Premature Infants

Summary: noninvasive ventilation has been used in preterm newborn with respiratory distress syndrome in an attempt to assist failure extubation. the investigators investigated failure extubation in infants gestational age less than or equal to 34 weeks and weights less than or equal to 1500 grams. neonates were randomized to noninvasive modalities support. 101 newborns were included in this study in three groups , group 1: nasal intermittent positive pressure ventilation (nippv) (n=36), group 2: nasal continuous positive airway pressure bubble (ncpap bubble) (n=33) and group 3: nasal continuous positive airway pressure bubble ventilator (ncpap ventilator) (n=32)

the infants were randomly allocated after extubation used a list of computer-generated randomization in nippv modes (with the following settings: positive inspiratory pressure (pip) \< 16 centimeters of water (cm h2o), positive end-expiratory pressure (peep) 4-5 centimeters of water (cm h2o, backup respiratory rate (rr) \< 18 cycles per minute flow 6-7 liters per minute (l / min) and inspiratory time (ti) according to the time constant for idae (0.30 to 0.34 seconds), and respirator seal to ncpap water tower was adjusted to 4-5 centimeters of water (cm h2o) peep, flow 6-7 liters per minute (l / min.) oxygen for both was adjusted to maintain arterial oxygen saturation between 85-95% the criteria for extubation were defined using a protocol by the clinic staff, confirmed by arterial blood gases and chest x-ray, as well as adjustments of the ventilator settings. vital signs, blood gas parameters and noninvasive brackets were recorded before, immediately, 15, 30, 45 minutes, 1(hour) h, 2h, 12h, 24h and 48 h after extubation were documented. neonatal morbidities were documented until discharge, among these are: patent ductus arterious, necrotizing enterocolitis, retinopathy of prematurity, intracranial hemorrhage and pneumothorax. data on achievement of prenatal, antenatal steroids and surfactant administration were documented. all newborns were natural porcine surfactant curosurf®. the total duration of mechanical ventilation and oxygen were documented from birth until discharge or death. the supplemental oxygen or mechanical ventilation days was defined as daily requirement of fraction of inspired oxygen (fio 2)\> 0.21 or ventilation \> 12 hours, respectively. the newborns were followed for all interaction until discharge (about 5 weeks).

Eligibility criteria:
inclusion criteria: * were eligible for the study * newborn (nb) ≤ 34 weeks and 500g to the weight of ≤ 1500 grams with a diagnosis of respiratory distress syndrome (rds) who had their first elective extubation. exclusion criteria: * excluded patients with cardiorespiratory system malformations * genetic disorders * neuromuscular disease and malformations of the central nervous system.

Keywords: newborn non invasive ventilation
cell proliferation in pulmonary hypertension. fdg-pet comparison between patients and healthy subjects

Conditions: Pulmonary Hypertension

Summary: pulmonary arterial hypertension (pah) and chronic thromboembolic pulmonary hypertension (cteph) are serious diseases with poor prognosis despite recent advances. currently, pulmonary hypertension (ph) is considered a cell proliferative disorder, which has not been adequately characterized due to the lack of markers. a better understanding of the mechanisms that regulate this proliferative disorder will allow the identification of new therapeutic targets for hp. the objective of the project is to identify cell proliferative processes in severe forms of ph. patients with pah (n=20), cteph (n=20) and healthy controls (n=20) will undergo characterization of micrornas (mirnas) contained within circulating microparticles (mps) analysis and mitochondrial functionality and fdg-pet to compare cell metabolism in the lungs and the right ventricle between patients and controls.


Eligibility criteria:
inclusion criteria: 1. patients with pah: * hemodynamic diagnosis of precapillary pulmonary hypertension: papm ≥25 mmhg, pcwp ≤15 mmhg * exclusion of group 2,3,4 or 5 2. patients with cteph: * hemodynamic diagnosis of precapillary pulmonary hypertension: papm ≥25 mmhg, pcwp ≤15 mmhg * persistence of thrombotic perfusion defects on pulmonary scintigraphy or angioct, after 3 months or more of correct anticoagulant therapy 3. healthy subjects * no known disease or condition * normal lung function, chest x-ray, ekg and blood chemistry and haematology exclusion criteria: * severe comorbidity. * pulmonary, pleural or rib cage disease interfering with fdg-pet acquisition * malignancy with exception of basocellular carcinoma * current smoker or former smoker (last 10 years or more than 10-year-pack). * pregnant or lactating women hyperglycemia (fasting above 200 mg/dl) * hypersensitivity to the product or its excipients
evaluating procedures for a study of the aya survivors coping and emotional needs toolkit

Conditions: Depression; Cancer; Adolescent; Young Adult; Adult

Summary: the investigators developed a digital intervention that aims to help adolescent and young adult cancer survivors (ayas) manage symptoms of depression. this tool includes daily mood tracking, a psychoeducational module about cancer and depression, four components that are based on evidence-based interventions for depression. the goal of this study is to evaluate the acceptability of procedures for a future trial in which the investigators will test which component or combination of components meaningfully contribute to improvements in depressive symptoms among ayas. additionally, the investigators will evaluate study feasibility as well as intervention acceptability, satisfaction, usability, and engagement.


Eligibility criteria:
inclusion criteria: * age at enrollment (adolescents 15-17, emerging adults 18-25, young adults 26-39) * age at diagnosis (adolescents 12-17, emerging adults 15-25, young adults 15-39) * time since completion of treatment: 1 month to 5 years * language: fluent in english (spoken and written) * technology: own smart phone with data plan exclusion criteria: * mental health: current diagnosis of severe or persistent mental illness * suicidality: severe suicidal ideation (including plan and intent)
clinical study of xpo1 inhibitor selinexor combined with copl in newly diagnosed advanced nk/t-cell lymphoma

Conditions: nk/T-cell Lymphoma; Newly Diagnosed; Advanced Lymphoma

Summary: patients with newly diagnosed, pathologically confirmed nk/t-cell lymphoma of stage iii-iv treated with xcopl regimen. 3 weeks for a cycle, with a total of 6-8 cycles.

patients with newly diagnosed, pathologically confirmed nk/t-cell lymphoma of stage iii-iv treated with xcopl regimen. 3 weeks for a cycle, with a total of 6-8 cycles. initial safety and pet-ct assessment were performed after 3 cycles of treatment (which could be delayed until 4 cycles of treatment in special cases). patients who achieved partial remission or above will continue the original regimen, and patients who did not achieve partial remission or above will perform re-biopsy and be excluded from the group. patients who remain partial remission by pet-ct evaluation after 6 cycles may switch to a second-line regimen (referring to nccn guidelines, gdp regimen combined with selinexor is recommended). chemotherapy will be performed for up to 8 cycles (followed by autologous or allogeneic hematopoietic stem cell transplantation), after which follow-up period was entered. it is recommended to perform ultrasound or ct evaluation, peripheral blood ctdna and ebv copy number every three months during the first year of follow-up, and pet-ct evaluation every half a year.

Eligibility criteria:
inclusion criteria: * age≥14 years, male or female; * pathologically confirmed newly diagnosed nk/t cell lymphoma according to who classification criteria 2016; * at least one measurable lesion, defined as bidimensionally measurable, intranodal lesion \> 1.5 cm in short axis and extranodal lesion \> 1.0 cm in short axis; * ecog score 0\~2; * clinical stage iii\~iv; * normal major organ function, meeting the following definitions: hematology: wbc ≥ 3.5 x 10 9/l, plt ≥ 75 x 10 9/l, hb ≥ 80 g/l; liver and kidney function: ast and alt ≤ 3.0 uln; tbil ≤ 2.0 mg/dl; ccr ≥ 60 ml/min; liver and kidney function impairment caused by tumor compression is not limited by this; fibrinogen: normal at first cycle * expected survival \> 6 months * agree to use effective contraception; * understand and voluntarily sign written informed consent exclusion criteria: * prior allogeneic hct (allo-hct) * active autoimmune disease * primary central nervous system lymphoma; * patients with infection which requiring treatment. could be re-enrollment after infection control; * known history of human immunodeficiency virus (hiv) infection * known hypersensitivity to the study drug or any of its excipients; * presence of other active malignancy requiring treatment that could interfere with this study; * patients with other conditions not suitable for enrollment as judged by the investigator.